We hope you find everything you need to understand how Idorsia intends to achieve its ambitious goals. If you need any further support please don't hesitate to reach out to us.

Contact

Investor Relations
Hegenheimermattweg 91
4123 Allschwil
Switzerland

Our strategy

Our strategy

Find out more about the key priorities that management has set in order to develop Idorsia into one of Europe’s leading biopharmaceutical company.

Development pipeline

Development pipeline

Idorsia has a diversified clinical development pipeline in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders, and orphan diseases.

Stay informed

Stay informed

Idorsia offers an electronic ‘Stay Informed’ service where subscribers can automatically receive updates via e-mail or SMS alert.

Event When
FY 2017 Financial Results reporting 6 February 2018
3 Months 2018 Financial Results reporting 19 April 2018
Annual General Meeting of Shareholders 24 April 2018
Half-Year 2018 Financial Results reporting 24 July 2018
9 Months 2018 Financial Results reporting 23 October 2018

 

Financial information

Financial information

Read all the latest financial information from Idorsia.